Abstract
Psoriasis in HIV-infected patients poses a distinct challenge to the dermatologist due to its increased severity, tendency to be refractory to common treatment modalities, and necessity for cautious use of immunosuppressive agents. Tumor necrosis factor-α inhibitors have been shown to be safe and effective for the treatment of psoriasis in the general population, but their role in the treatment of HIV-positive patients is still unclear. The use of the tumor necrosis factor-α inhibitor adalimumab for the treatment of psoriasis in HIV-positive patients has yet to be reported. We present the case of a 49-year-old HIV-positive man with severe plaque psoriasis who has been successfully treated with adalimumab for the past 30 months with no adverse events related to treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 869-871 |
| Number of pages | 3 |
| Journal | Journal of Drugs in Dermatology |
| Volume | 13 |
| Issue number | 7 |
| State | Published - Jan 1 2014 |
Fingerprint
ASJC Scopus subject areas
- Dermatology
Cite this
Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient. / Lindsey, Scott F.; Weiss, Jonathan; Lee, Eric S.; Romanelli, Paolo.
In: Journal of Drugs in Dermatology, Vol. 13, No. 7, 01.01.2014, p. 869-871.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient
AU - Lindsey, Scott F.
AU - Weiss, Jonathan
AU - Lee, Eric S.
AU - Romanelli, Paolo
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Psoriasis in HIV-infected patients poses a distinct challenge to the dermatologist due to its increased severity, tendency to be refractory to common treatment modalities, and necessity for cautious use of immunosuppressive agents. Tumor necrosis factor-α inhibitors have been shown to be safe and effective for the treatment of psoriasis in the general population, but their role in the treatment of HIV-positive patients is still unclear. The use of the tumor necrosis factor-α inhibitor adalimumab for the treatment of psoriasis in HIV-positive patients has yet to be reported. We present the case of a 49-year-old HIV-positive man with severe plaque psoriasis who has been successfully treated with adalimumab for the past 30 months with no adverse events related to treatment.
AB - Psoriasis in HIV-infected patients poses a distinct challenge to the dermatologist due to its increased severity, tendency to be refractory to common treatment modalities, and necessity for cautious use of immunosuppressive agents. Tumor necrosis factor-α inhibitors have been shown to be safe and effective for the treatment of psoriasis in the general population, but their role in the treatment of HIV-positive patients is still unclear. The use of the tumor necrosis factor-α inhibitor adalimumab for the treatment of psoriasis in HIV-positive patients has yet to be reported. We present the case of a 49-year-old HIV-positive man with severe plaque psoriasis who has been successfully treated with adalimumab for the past 30 months with no adverse events related to treatment.
UR - http://www.scopus.com/inward/record.url?scp=84904119764&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904119764&partnerID=8YFLogxK
M3 - Article
VL - 13
SP - 869
EP - 871
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
SN - 1545-9616
IS - 7
ER -